Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 20/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 20/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671869 | 0.95 | CHRM2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2793984 | 0.92 | CHRM2 (0.37) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3673741 | 0.89 | CHRM2 (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3677129 | 0.89 | CHRM2 (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4509630 | 0.79 | CHRM2 (0.55) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3675633 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6400846 | 0.78 | CHRM2 (0.57) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3040211 | 0.78 | CHRM2 (0.57) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6401757 | 0.78 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6399731 | 0.76 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CHRM2 84/4885CHRM1 158/4885CHRM3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.